title: A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients.
abstract: Extensive prior treatment with cytotoxic agents is associated with impaired mobilization of hematopoietic cells. To assess the effect of a single course of standard-dose chemotherapy (CT), we compared the results of filgrastim-induced mobilization among two sequential groups of grade III-IV malignant glioma patients included in a hematopoietic transplantation program. The first group (21 patients) had never been treated with CT until 2 days after surgery, when they received a course of 100 mg/m2 BCNU (i.v.) and 100 mg intracarotid cisplatin for cytoreduction (not for mobilization). At 1 month after this CT, they were mobilized with 12 microg/kg filgrastim. The second group (22 patients) was mobilized with the same dose of filgrastim directly after the surgery, without having ever received any prior CT. The blood level of CD34+ cells was significantly lower in the CT-treated patients, both on the fourth day of filgrastim (15 vs 36 cells x 10(6)/l; P=0.01) and on the fifth (25 vs 58 cells x 10(6)/l; P=0.003), as it was the number of CD34+ cells collected per apheresis (1.3 vs 3.5 x 10(6)/l; P<0.0005). The toxic effect of a single course of BCNU-cisplatin CT led to significant impairment of the filgrastim-induced mobilization response.
authors.affiliation: Cell Therapy Area, Clínica Universitaria de Navarra, Pamplona, Spain. jpcalvo@unav.es
authors.forename: J
authors.initials: J
authors.lastname: Pérez-Calvo
authors.forename: O
authors.initials: O
authors.lastname: Fernàndez
authors.forename: J J
authors.initials: JJ
authors.lastname: Aristu
authors.forename: J M
authors.initials: JM
authors.lastname: Aramendia
authors.forename: J
authors.initials: J
authors.lastname: Rifón
authors.forename: F
authors.initials: F
authors.lastname: Prosper
authors.forename: M
authors.initials: M
authors.lastname: Bendandi
authors.forename: E
authors.initials: E
authors.lastname: Rocha
authors.forename: S
authors.initials: S
authors.lastname: Martin-Algarra
mesh_terms: D000328:Adult; D018952:Antigens, CD34 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000188:drug therapy*; D002330:Carmustine / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D003131:Combined Modality Therapy; D005910:Glioma / Q000188:drug therapy*; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008875:Middle Aged
chemical_list: D018952:Antigens, CD34; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D002945:Cisplatin; D002330:Carmustine